CancerDrs Find care

Prostate Cancer clinical trials in Georgia

19 actively recruiting prostate cancer trials at 9 sites across Georgia.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …

Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Georgia:
  • Grady Health System — Atlanta, Georgia
  • Emory Proton Therapy Center — Atlanta, Georgia
  • Emory University Hospital Midtown — Atlanta, Georgia
  • Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
  • Emory Saint Joseph's Hospital — Atlanta, Georgia
Phase 3 Recruiting Academic/Other

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tum…

Sponsor: NRG Oncology
NCT ID: NCT04134260
Sites in Georgia:
  • Grady Health System — Atlanta, Georgia
  • Emory Proton Therapy Center — Atlanta, Georgia
  • Emory University Hospital Midtown — Atlanta, Georgia
  • Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
  • Emory Saint Joseph's Hospital — Atlanta, Georgia
Phase 3 Recruiting Industry

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.

Sponsor: AstraZeneca
NCT ID: NCT06120491
Sites in Georgia:
  • Research Site — Atlanta, Georgia
Phase 2, Phase 3 Recruiting Industry

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA ta…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06780670
Sites in Georgia:
  • University Cancer and Blood Center LLC — Athens, Georgia
Phase 2 Recruiting NIH

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Georgia:
  • Emory University Hospital Midtown — Atlanta, Georgia
  • Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
  • Emory Saint Joseph's Hospital — Atlanta, Georgia
  • Emory Johns Creek Hospital — Johns Creek, Georgia
Phase 1, Phase 2 Recruiting Industry

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas.

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT04104776
Sites in Georgia:
  • Winship Cancer Institute of Emory University — Atlanta, Georgia
Phase 2 Recruiting Federal

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therap…

Sponsor: VA Office of Research and Development
NCT ID: NCT05011383
Sites in Georgia:
  • Atlanta VA Medical and Rehab Center, Decatur, GA — Decatur, Georgia
Phase 2 Recruiting Industry

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC …

Sponsor: Kyntra Bio
NCT ID: NCT06842498
Sites in Georgia:
  • Winship Cancer Institute, Emory University — Atlanta, Georgia
Phase 2 Recruiting Academic/Other

An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion Technique

This phase II trial evaluates an imaging technique called 18F-rhPSMA-7.3 positron emission tomography (PET)-multiparametric (mp) magnetic resonance imaging (MRI) in identifying tumor tissue in men suspected to have prostate cancer. This cl…

Sponsor: Emory University
NCT ID: NCT06865768
Sites in Georgia:
  • Emory University Hospital — Atlanta, Georgia
Phase 1, Phase 2 Recruiting Industry

Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients

This phase 1b open label, dose-escalating investigation study is to evaluate the dose dependent initial efficacy of the use of MT218 injection for biomarker targeted MR molecular imaging (MRMI) of prostate cancer in patients scheduled for …

Sponsor: Songqi Gao
NCT ID: NCT06262139
Sites in Georgia:
  • Emory University — Atlanta, Georgia
Phase 1 Recruiting Industry

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is a…

Sponsor: Nammi Therapeutics Inc
NCT ID: NCT06582017
Sites in Georgia:
  • Emory University - Winship Cancer Institute — Atlanta, Georgia
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Georgia:
  • Northeast Georgia Medical Center Braselton — Braselton, Georgia
  • Atlanta VA Medical Center — Decatur, Georgia
  • Northeast Georgia Medical Center-Gainesville — Gainesville, Georgia
  • The Longstreet Clinic - Gainesville — Gainesville, Georgia
  • Low Country Cancer Care — Savannah, Georgia
Recruiting Academic/Other

RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT

The RSSearch® Registry is an international multi-year database designed to track SRS/SBRT (Stereotactic Radiosurgery/Stereotactic Body Radiation Therapy) utilization, treatment practices and outcomes to help determine, over time, the most …

Sponsor: The Radiosurgery Society
NCT ID: NCT01885299
Sites in Georgia:
  • Southeast Georgia Health System — Brunswick, Georgia
NA Recruiting Academic/Other

Improving Health Literacy in African-American Prostate Cancer Patients

Investigators propose an observational interview study to explore how patients understand treatment conversations with their physicians within the framework of health literacy. The study team will test whether patients' understanding of tr…

Sponsor: Emory University
NCT ID: NCT03322891
Sites in Georgia:
  • Atlanta VA Medical Center — Atlanta, Georgia
  • Grady Memorial Hospital — Atlanta, Georgia
  • Emory University — Atlanta, Georgia
  • Emory Saint Joseph's Hospital — Atlanta, Georgia
NA Recruiting Academic/Other

Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer

This phase II trial investigates whether proton radiation therapy directed to the prostate tumor, pelvic, and para-aortic lymph nodes, is an effective way to treat patients with high-risk or lymph node positive prostate cancer who are rece…

Sponsor: Emory University
NCT ID: NCT04725903
Sites in Georgia:
  • Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20